Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle

James West, Karen Fagan, Wolfgang Steudel, Brian Fouty, Kirk Lane, Julie Harral, Marloes Hoedt-Miller, Yuji Tada, John Ozimek, Rubin Tuder, David M. Rodman

Abstract—Bone morphogenetic peptides (BMPs), a family of cytokines critical to normal development, were recently implicated in the pathogenesis of familial pulmonary arterial hypertension (PAH). The type-II receptor (BMPRII) is required for recognition of all BMPs, and targeted deletion of BMPRII in mice results in fetal lethality before gastrulation. To overcome this limitation and study the role of BMP signaling in postnatal vascular disease, we constructed a smooth muscle–specific transgenic mouse expressing a dominant-negative BMPRII under control of the tetracycline gene switch (SM22-tet-BMPRII\textsuperscript{delx4} mice). When the mutation was activated after birth, mice developed increased pulmonary artery pressure, RV/LV+S ratio, and pulmonary arterial muscularization with no increase in systemic arterial pressure. Studies with SM22-tet-BMPRII\textsuperscript{delx4} mice support the hypothesis that loss of BMPRII signaling in smooth muscle is sufficient to produce the pulmonary hypertensive phenotype. (Circ Res. 2004;94:1109-1114.)

Key Words: artery ■ bone morphogenetic peptide ■ hypertension ■ smooth muscle ■ vascular

A

association between abnormal bone morphogenetic peptide (BMP) signaling and pulmonary vascular disease was suggested by genetic studies of familial pulmonary arterial hypertension (PAH), a disorder characterized by the pathological development of increased pressure and structural remodeling in the pulmonary circulation later in life.\textsuperscript{1,2} Fifteen to 25% of cases of PAH occur in families, with autosomal-dominant inheritance, and in the year 2000, two groups independently identified the presence of mutations in the BMPRII gene in familial PAH.\textsuperscript{3,4} Subsequently, approximately 25% of sporadic cases of PAH were also found to be associated with mutations in BMPRII.\textsuperscript{5}

Dissecting the function of BMPRII using transgenic mice has identified a critical role for BMP signaling in development.\textsuperscript{6} Although there is redundancy at the level of ligands, type I receptors, intra- and extracellular inhibitors and downstream signaling via SMADs, functional BMPRII is an absolute requirement for BMP signaling. Consequently, BMPRII\textsuperscript{−/−} mice die early in development, before gastrulation, whereas BMPRII\textsuperscript{+/−} mice develop normally and have no apparent phenotype.\textsuperscript{7} To overcome the developmental lethality identified by traditional transgenic approaches, we constructed a conditional, tissue-specific BMPRII transgenic mouse, using a smooth muscle cell–specific promoter and a dominant-negative BMPRII identified in a family with PAH.\textsuperscript{8} Using these mice, we asked two questions: (1) is expression of a strong loss-of-function mutation in BMPRII sufficient to produce pulmonary hypertension, and (2) is loss of BMPRII function in smooth muscle alone sufficient to produce pulmonary hypertension?

Materials and Methods

Construction of SM22-tet-BMPRII\textsuperscript{delx4} Transgenic Mice

The mice were generated at the University of Cincinnati Transgenic Mouse Science from plasmids we provided. The murine SM22 promoter (488 bp starting 340 bp before the start site and extending 148 bp into the 5′ UTR) was used to drive expression of the reverse tetracycline transactivator (rtTA), and a septad of the tetracycline response element and minimal CMV promoter were used to drive expression of the mutant BMPRII mutation on the FVB/N background (Figure 1).\textsuperscript{9,10} The BMPRII mutation, identified by Machado et al in family UK21, was insertion of a "T" at base 594 in the kinase (4th) domain of the protein, resulting in a premature stop 18 amino acids into the kinase domain.\textsuperscript{8} We refer to this as BMPRII\textsuperscript{del554} to indicate that it is a deletion from the 4th domain onward. After birth, mothers were fed doxycycline in food (1 mg/g) while nursing, and after weaning, SM22-tet-BMPRII\textsuperscript{del554} mice were fed doxycycline until age 8 weeks when phenotyping was performed. Control mice were double transgenic littermates not fed doxycycline. All procedures were approved by the University of Colorado institutional animal use committee.

BMPRII Activity Assay In Vitro

Semi-confluent human pulmonary artery smooth muscle cells (SMCs) (Clonetics) were cotransfected (lipofectamine PLUS) with a CMV-driven BMPRII\textsuperscript{delx4} plasmid (or empty vector) and a SMAD-
responsive luciferase construct. Every well also received a β-galactosidase expression plasmid, for normalization to transfection efficiency. Whereas transfection efficiency was only 15% to 20%, because the two plasmids were mixed and transfected together, cells expressing the reporter also expressed the mutant BMP, and thus the luciferase measurements were not significantly affected by transfection efficiency. Forty-eight hours after transfection, either recombinant human BMP2 (Sigma) or vehicle was added to wells, and after 3 hours, cells were assayed for luciferase activity.

SM22-Driven Transgene Localization In Vivo
SM22-driven rtTA transgenic mice were crossbred with TetO7-CMV-luciferase mice (Jackson Labs) or TetO7-lacZ mice (gift of L. Chodosh, University of Pennsylvania School of Medicine, Philadelphia, Pa.). Eight-week-old mice were fed doxycycline in food (1 mg/g) for 4 days, euthanized, and approximately 20 mg of tissue from each organ homogenized for use with the promega luciferase assay system, or formalin-fixed tissue used for lacZ immunohistochemistry.

Phenotyping
Phenotyping SM22-tet-BMPRII<sup>delx4+</sup> Mice
The cardiovascular phenotype of SM22-tet-BMPRII<sup>delx4+</sup> mice was evaluated using in vivo hemodynamic measurements. The Table shows average data for hemodynamic parameters. Heart rate and LV systolic pressure did not differ in doxycycline-fed and -unfed mice. RV and LV diastolic pressure was near zero in all mice (data not shown). As Figure 3 shows, right ventricular (RV) systolic pressure was nearly 2-fold increased in doxycycline-fed transgenic mice, compared with non–doxycycline-fed littersmates. Measurement of RV relative weight confirmed the presence of sustained pulmonary hypertension, with a 30% increase in RV/LV+septum weight in doxycycline-fed transgenics. There was a modest increase in hematocrit in doxycycline-fed transgenic mice, although not of a magnitude capable of increasing blood viscosity or pressure. To evaluate the effect of hypoxia, arterial blood gas studies in mice spontaneously breathing room air were performed. Arterial Po₂ (Pao₂) did not differ between groups (dox<sup>-</sup>, 74±5 versus dox<sup>+</sup>, 78±3 mm Hg; P=nS, n=4), and Pco₂ and pH were normal (data not shown). To evaluate the possibility that mice expressing BMPRII<sup>delx4+</sup> were more susceptible to the mild effects of hypoxia in Denver (Pao₂ 75 to 80 mm Hg versus 110 to 120 mm Hg at sea level), two pregnant double transgenic mice were placed into hyperbaric chambers that maintained normal sea level ambient pressure.
and \( P_{\text{ao}} \) during pregnancy and weaning of 10 pups that were raised in the chambers until 8 weeks of age, when they were catheterized. The table shows that in these doxycycline-fed transgenic mice, RV systolic pressure was intermediate to Denver altitude doxycycline-fed and control mice. RV/LV systolic pressure was intermediate to Denver altitude doxycycline-fed mice versus 0.360 ± 0.015 in sea level doxycycline-fed mice and 0.242 ± 0.023 in control mice \((P<0.01 \text{ all groups})\).

To evaluate structural abnormalities, we performed immunohistochemical staining for muscular pulmonary and systemic vessels. C, Localization of BMPRIII delx4 expression in the lungs of SM22-tet-luciferase transgenic mice: SM22-rtTA mice were crossed with tetO7-luciferase mice, and the localiza- tion of reporter gene expression was assayed by \( \beta \)-gal immunostaining. In the photomicrograph \((40 \times \text{ objective}) \), the arrow points to \( \beta \)-gal expression in smooth muscle of a large \( \text{L} \) pulmonary artery. Little immunostaining was seen in the capillary endothelial cells and epithelial cells of the alveolar wall (A). D, Distribution of BMPRIII delx4 expression by the tetracycline gene switch in SM22-tet-BMPRIII delx4 mice. SM22-rtTA mice were crossed with tetO7-BMPRIII delx4 mice and lungs from double transgenic progeny homogenized for RNA isolation and quantitative RT/PCR determination of BMPRIII delx4 transgene expression. Open circles are lung tissue from mice not fed doxycycline, and filled circles are mice fed doxycycline. In transgenic mice fed doxycycline, there was a strong correlation between SM22-driven rtTA expression and the amount of BMPRIII delx4 transgene detected \((P<0.001)\). These experiments establish that SM22-tet-BMPRIII delx4 transgenic mice are viable and express a dominant-negative BMPRIII receptor in pulmonary and systemic vascular smooth muscle only when fed doxycycline.

### Hemodynamics

<table>
<thead>
<tr>
<th></th>
<th>-Dox ((n=8))</th>
<th>+Dox ((n=15))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate, bpm</td>
<td>266 ± 43</td>
<td>262 ± 25</td>
</tr>
<tr>
<td>LV systolic, mm Hg</td>
<td>110 ± 5</td>
<td>116 ± 5</td>
</tr>
<tr>
<td>RV systolic (Denver), mm Hg</td>
<td>32.7 ± 1.3</td>
<td>55.1 ± 2.2*</td>
</tr>
<tr>
<td>RV systolic (sea level), mm Hg</td>
<td>ND</td>
<td>44.0 ± 2.0*† ((n=10))</td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>38.3 ± 2.4</td>
<td>43.9 ± 1.2‡</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. *\( P<0.01 \) from Denver–Dox; †\( P<0.01 \) from Denver +Dox; ‡\( P<0.05 \) from -Dox. ND indicates not determined.

and abnormal development are not the reason for the pulmonary hypertensive phenotype in these mice.\(^{15,16}\)

Using quantitative morphometry, we found increased medial thickness of muscular pulmonary arteries in doxycycline-fed SM22-tet-BMPRIII delx4 mice. In addition, there was increased muscularization of small pulmonary arteries at the level of alveolar ducts. These abnormalities recapitulate one of the primary lesions seen in humans with PAH and suggest that an effect of loss of SMC BMPRII signaling is the development of increased muscularization of pulmonary arteries, leading either directly or via associated vasoconstriction to increased pulmonary vascular resistance. Figure 4 demonstrates the morphological findings in SM22-tet-BMPRIII delx4 mice.

### Discussion

Reports that mutations in BMPRII were associated with selective pulmonary arterial hypertension in humans suggested a link between BMP signaling and the occurrence of the disease but did not establish whether mutations were sufficient to produce the disease phenotype or simply permissive. Further, as the mutations were somatic and BMPRII is ubiquitously expressed, they did not establish the relevant cell types in which abnormal BMP signaling leads to the disease phenotype.

The first goal of our study was to test the hypothesis that abnormal BMP signaling resulting from expression of a loss-of-function mutation was sufficient to produce the disease phenotype and, consistent with this hypothesis, SM22-
tet-BMPRII delx4/H11001 mice developed pulmonary hypertension by 8 weeks of age. Like other type II receptors in the TGFβ superfamily, signaling function of BMPRII requires binding to ligand, dimerization with, and phosphorylation of a type I receptor and, finally, phosphorylation and activation of a signaling SMAD. The mutation we chose for generation of the transgenic has a premature stop codon with truncation early in the kinase domain. Functionally the mutation resulted in dominant-negative inhibition of receptor kinase activity (as assessed by the inability of BMP to activate SMAD signaling). Recently, it was also reported that the N-terminal portion of BMPRII binds to, and inactivates the cytoskeletal regulator, LIM-kinase. On dimerization with a type I receptor, BMPRII releases LIM-kinase, allowing it to phosphorylate its substrates. Although we did not test this property directly, overexpression of delx4/H11001 would also function as a dominant-negative in this regard, as endogenously expressed wild-type BMPRII that did not bind BMPRIH11001 delx4/H11001 would continue to inactivate LIM-kinase. Therefore, although our studies support the hypothesis that loss-of-function of BMPRII produces pulmonary arterial hypertension, additional studies will be required to determine if defective receptor kinase activity, inactivation of LIM-kinase, or a combination of the two are responsible for the phenotype.

While our studies support the hypothesis that a mutation resulting in sufficient loss of BMPRII function is capable of producing the disease phenotype, they do not rule out the possibility that disease occurrence in individuals with less severe BMPRII mutations, such as haploinsufficiency, requires the presence of an environmental or genetic costimulus. Consistent with the hypothesis that mutations in BMPRII can synergize with environmental factors, SM22-tet-BMPRII delx4/H11001 mice raised in Denver developed more severe pulmonary hypertension than those raised at sea level, although significant pulmonary hypertension was seen even in the "low altitude" group. This suggests that, like humans with idiopathic PAH, even mild hypoxia exacerbates the phenotype of SM22-tet-BMPRII delx4/H11001 mice.

The second goal of our study was to test the hypothesis that inducing abnormal BMPRII function selectively in smooth muscle was sufficient to produce the disease phenotype, and our findings support that hypothesis as well. BMPRII is expressed in a number of lung cell types, including smooth muscle, endothelium, epithelium, and macrophages. Prior studies showed that BMPs could control smooth muscle cell proliferation in vitro. Therefore, we chose to target the mutation to smooth muscle. Morphometric analysis showed that there was increased medial smooth muscle thickness and a tendency for distal muscularization of small pulmonary arteries. These findings recapitulate one of the pathological hallmarks of PAH. However, the magnitude of the change was small, relative to the large increase in pulmonary artery pressure and, unlike advanced PAH, no intimal lesions were seen. A potential explanation for this paradox is the possibility that a component of the pulmonary hypertension in 8-week-old SM22-tet-BMPRII delx4/H11001 mice was due to enhanced vasoconstriction. This is consistent with a two-phase hypothesis for the pathogenesis of PAH in which early
disease is characterized by enhanced vasoconstriction and minimal remodeling and later disease by progressive remodeling and little vasoconstriction. Further studies will be needed to define the mechanisms underlying the increase in tone and determine if remodeling becomes more pronounced as the mice age.

Interestingly, even though the SM22 promotor we used resulted in expression in systemic as well as pulmonary smooth muscle, phenotypic abnormalities were only seen in the lung. Although we were not able to quantify the relative amount of mutant receptor protein expressed in systemic versus pulmonary resistance arteries, luciferase expression in the aortas of SM22-tet-luc mice suggested that, consistent with the literature on SM22 expression, the promotor was active in systemic arteries. Thus, it appears that under our experimental conditions, BMP signaling played a more significant role in maintaining normal tone and structure of the pulmonary than systemic circulation. It is possible that in other circumstances, such as systemic atherosclerosis, BMP signaling may modulate systemic vascular disease as well.

Although we do not have an explanation for the pulmonary vascular specificity of the phenotype, it is consistent with the lack of systemic vascular disease in patients with pulmonary arterial hypertension and suggests that BMP signaling plays a unique role in controlling tone and structure in the pulmonary circulation.

Although our studies support the hypothesis that BMPRII mutations are sufficient to produce pulmonary arterial hypertension and that the mutation need only be expressed in smooth muscle to produce the phenotype. Furthermore, the lack of a major systemic vascular phenotype in these mice suggests that BMPRII signaling is uniquely important in the pulmonary circulation. SM22-tet-BMPRIIdelx4 mice should provide a useful model to study the molecular and physiological abnormalities in pulmonary arterial hypertension and facilitate the discovery and preclinical testing of potential new therapies.

Acknowledgments

Funding sources included HL48038, HL57282, and HL71596 (D.M.R.) from the NIH National Heart, Lung, and Blood Institute and Mentored Scientist Training (J.W.) and Established Investigator Awards (K.F.) from the American Heart Association. We thank Ivan Whitsett for advice in constructing the conditional transgenic mice.

References


Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle

James West, Karen Fagan, Wolfgang Steudel, Brian Fouty, Kirk Lane, Julie Harral, Marloes Hoedt-Miller, Yuji Tada, John Ozimek, Rubin Tuder and David M. Rodman

_Circ Res._ 2004;94:1109-1114; originally published online March 18, 2004;
doi: 10.1161/01.RES.0000126047.82846.20

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/94/8/1109

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org//subscriptions/